Caricamento...
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
PURPOSE: The SP142 PD-L1 assay is a companion diagnostic for atezolizumab in metastatic triple-negative breast cancer (TNBC). We strove to understand the biological, genomic, and clinical characteristics associated with SP142 PD-L1 positivity in TNBC patients. METHODS: Using 149 TNBC formalin-fixed...
Salvato in:
| Pubblicato in: | Breast Cancer Res Treat |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer US
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8233296/ https://ncbi.nlm.nih.gov/pubmed/33770313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-021-06193-9 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|